Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...

Ovarian cancer is caused by a harmful overgrowth of cells in and around the ovaries. The cancer can start in the lining of the ovary or fallopian tube, the supportive tissue, or in the egg cell. There ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

That’s when the same type of cancer comes back after you have completed treatment and gone into remission. But some cancers, such as ovarian cancer, also raise your risk for developing a ...

When tumor cells leave ascites, it can be observed that their proliferation ability is significantly weakened. In ovarian cancer, ascites occurs in a considerable proportion of patients, and the ...

Most women with epithelial ovarian cancer are diagnosed with stage III ... repeated paracentesis for ascites, and/or multiple thoracentesis for pleural effusions 1A Growth limited to one ovary ...

Ovarian cancer is the sixth most common cancer worldwide ... repeated paracentesis for ascites, and/or multiple thoracentesis for pleural effusions 1A Growth limited to one ovary; no tumor on ...

FGF7 protein was significantly higher in tumors than in ascites in independent mouse models and clinical specimens. Serum FGF7 protein levels above the median of 25 patients with ovarian cancer were ...

Patients who were excluded included those with ascites, recurrences other than primary or with ... we observed no additional benefit in PFS in patients with platinum-sensitive recurrent [ovarian ...